Complementary Strand MicroRNAs Mediate Acquisition of Metastatic Potential in Colonic Adenocarcinoma

Chen, Dung Tsa; Hernandez, Jonathan M.; Shibata, David; McCarthy, Susan; Humphries, Leigh Ann; Clark, W. Edwin; Elahi, Abul; Gruidl, Mike; Coppola, Domenico; Yeatman, Timothy J.

doi:10.1007/s11605-011-1815-0

Cited by 57 publications

(46 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following selection criteria were used to narrow the list. First, miRNAs that represented a complementary strand (as indicated by a “star”) were excluded from further analysis based upon the concern that complementary strands could be unstable and degraded (8 of 34) [21]. A bioinformatics approach was taken as per the National Center for Biotechnology and Informatics (NCBI) and miRBase databases (www.…”

Section: Methodsmentioning

confidence: 99%

MicroRNA Expression Differentiates Squamous Epithelium from Barrett’s Esophagus and Esophageal Cancer

et al. 2013

View full text Add to dashboard Cite

Background Current strategies fail to identify most patients with esophageal adenocarcinoma (EAC) before the disease becomes advanced and incurable. Given the dismal prognosis associated with EAC, improvements in detection of early-stage esophageal neoplasia are needed. Aims We sought to assess whether differential expression of microRNAs could discriminate between squamous epithelium, Barrett’s esophagus (BE), and EAC. Methods We analyzed microRNA expression in a discovery cohort of human endoscopic biopsy samples from 36 patients representing normal squamous esophagus (n=11), BE (n=14), and high-grade dysplasia (HGD)/EAC (n=11). RNA was assessed using microarrays representing 847 human microRNAs followed by qRT-PCR verification of nine microRNAs. In a second cohort (n=18), qRT-PCR validation of five miRNAs was performed. Expression of 59 microRNAs associated with BE/EAC in the literature was assessed in our training cohort. Known esophageal cell lines were used to compare miRNA expression to tissue miRNAs. Results After controlling for multiple comparisons, we found 34 miRNAs differentially expressed between squamous esophagus and BE/EAC by microarray analysis. However, miRNA expression did not reliably differentiate non-dysplastic BE from EAC. In the validation cohort, all five microRNAs selected for qRT-PCR validation differentiated between squamous samples and BE/EAC. Microarray results supported 14 of the previously reported microRNAs associated with BE/EAC in the literature. Cell lines did not generally reflect miRNA expression found in vivo. Conclusions These data indicate that miRNAs differ between squamous esophageal epithelium and BE/EAC, but do not distinguish between BE and EAC. We suggest prospective evaluation of miRNAs in patients at high risk for EAC.

show abstract

Section: Methodsmentioning

confidence: 99%

MicroRNA Expression Differentiates Squamous Epithelium from Barrett’s Esophagus and Esophageal Cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Consequently, two datasets (GSE38832 [23] and GSE29621 [24]) were included in this study. Microarray processing and lncRNA screening Raw CEL files were downloaded and imported into R programming software through affy [25] Bioconductor package.…”

Section: Crc Datasetsmentioning

confidence: 99%

A Six-LncRNA Expression Signature Associated with Prognosis of Colorectal Cancer Patients

Zhao

Shang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Colorectal cancer (CRC) is one of the most common malignant tumor with high migration and invasion capacity. Long non-coding RNAs (lncRNAs) have been identified to influence multiple cancers progression through competitively binding microRNAs (miRNAs). In this study, we proposed to develop a lncRNA-based signature for CRC survival outcomes. Methods: LncRNA expression profiles of CRC patients were extracted from the Gene Expression Omnibus (GEO) data sets GSE38832 (training set) and GSE29621 (testing set) . Associations between lncRNA expression and CRC disease free survival (DFS) were evaluated through univariate Cox regression analysis, and prognosis signature constructed by combination of weighted lncRNA expression values were obtained through multivariate Cox regression analysis. Robustness of the prognosis signature was evaluated through receiver operating characteristics analysis in the testing set. Results: A weighted prognosis signature of six lncRNAs, including LINC01583, LINC00276, LUNAR1, DKFZp434J0226, SFTA1P and OGFOD3, was yielded from multivariate Cox regression analysis. Samples with significantly different DFS dislayed distinct signatures, indicating considerable predictory accuracy of this expression signature. Conclusion: Robustness of the prognosis signature was evaluated in the testing set through Kaplan-Meier and receiver operating characteristics (ROC) analysis. Furthermore, functional enrichment analysis of lncRNAs suggested significant enrichment of cancer related pathways. Our results revealed the promise of lncRNAs as prognostic biomarkers.

show abstract

“…Let-7 family members that include 14 isomers were of the most studied miRNAs that act as a tumour suppressor through targeting growth suppressors such as RAS and MMP11, and oncogenes such as PBX3 and NIRF (Akao et al, 2006a;Han et al, 2012;Wang et al, 2012a). Another important miRNA is the miR-200 family which found to be associated with metastasis inhibition by targeting the transcriptional repressor zinc-finger E-box binding homeobox 1 (ZEB1) in CRC and shortly after that miR-200c found to be downreglated in CRC cells (Burk et al, 2008;Chen et al, 2012a;. Whereas several miRNAs have been found to be over-expressed or under-expressed in CRC samples compared to normal adjacent colorectal tissues, the role of the differentially expressed miRNAs in colorectal tumorigenesis is not fully understood.…”

Section: Dysregulated Mirnas In Tissue Samples and Crc Cell Linesmentioning

confidence: 99%

MicroRNAs in Colorectal Cancer: from Diagnosis to Targeted Therapy

Orang¹,

Barzegari²

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the major healthcare problems worldwide and its processes of genesis include a sequence of molecular pathways from adenoma to carcinoma. The discovery of microRNAs, a subset of regulatory non-coding RNAs, has added new insights into CRC diagnosis and management. Together with several causes of colorectal neoplasia, aberrant expression of oncomiRs (oncogenic and tumor suppressor miRNAs) in cancer cells was found to be indirectly result in up-or down-regulation of targeted mRNAs specific to tumor promoter or inhibitor genes. The study of miRNAs as CRC biomarkers utilizes expression profiling methods from traditional tissue samples along with newly introduced non-invasive samples of faeces and body fluids. In addition, miRNAs could be employed to predict chemo-and radio-therapy responses and be manipulated in order to alleviate CRC characteristics. The scope of this article is to provide a comprehensive review of scientific literature describing aberrantly expressed miRNAs, and consequently dysregulation of targeted mRNAs along with the potential role of miRNAs in CRC diagnosis and prognosis, as well as to summarize the recent findings on miRNA-based manipulation methods with the aim of advancing in anti-CRC therapies.

show abstract

Complementary Strand MicroRNAs Mediate Acquisition of Metastatic Potential in Colonic Adenocarcinoma

Cited by 57 publications

References 36 publications

MicroRNA Expression Differentiates Squamous Epithelium from Barrett’s Esophagus and Esophageal Cancer

MicroRNA Expression Differentiates Squamous Epithelium from Barrett’s Esophagus and Esophageal Cancer

A Six-LncRNA Expression Signature Associated with Prognosis of Colorectal Cancer Patients

MicroRNAs in Colorectal Cancer: from Diagnosis to Targeted Therapy

Contact Info

Product

Resources

About